SCHEMBL4154654

SCHEMBL4154654

COc1cc(NC(=N)N)ccc1N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
HTT P42858 2/20 0.51
MAPT P10636 9/20 0.51
PKM P14618 1/20 0.51
TP53 P04637 1/20 0.51
THRB P10828 1/20 0.51
MAPK10 P53779 2/20 0.50
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
TNIK Q9UKE5 3/20 0.47
KCNH2 Q12809 2/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
HCRTR1 O43613 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172234 0.87 GAA (0.51) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
SCHEMBL4173591 0.83 MAPT (0.47) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
SCHEMBL4166402 0.81 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
SCHEMBL27674823 0.80 HTT (0.59) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
SCHEMBL4161854 0.80 MAPT (0.45) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
Bicarbonate SCHEMBL3549019 0.80 KMT2A (0.62) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
Bicarbonate SCHEMBL3548870 0.79 HTT (0.61) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
SCHEMBL4162412 0.78 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
Bicarbonate SCHEMBL28763043 0.78 HTT (0.60) SMN1; SMN2ALDH1A1MEN1KMT2AHTT
SCHEMBL4170567 0.77 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 SMN1; SMN2 2335/4885ALDH1A1 2743/4885MEN1 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.